Wilbanks Smith & Thomas Asset Management
ATRA icon

Wilbanks Smith & Thomas Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4
Closed -$4K – 420
2018
Q3 		$4K Buy
+4
New +$3.91K ﹤0.01% 1254

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ATRA Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Atara Biotherapeutics (ATRA) in Q4 2018, closing a stake of 4 shares — an estimated $4K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ATRA in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 121 funds tracked by Wall St. Rank hold ATRA as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Atara Biotherapeutics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 4 Atara Biotherapeutics shares in Q4 2018, an estimated $4K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Atara Biotherapeutics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Atara Biotherapeutics position peaked at $4K in Q3 2018.
  • 121 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.